

February 1, 2024

## Q3FY24 Result Update

Change in Estimates |  Target |  Reco

### Change in Estimates

	Current		Previous	
	FY25E	FY26E	FY25E	FY26E
Rating	BUY		BUY	
Target Price	1,640		1,280	
Sales (Rs. m)	5,36,409	5,95,968	5,40,407	5,98,295
% Chng.	(0.7)	(0.4)		
EBITDA (Rs. m)	1,49,128	1,74,116	1,50,752	1,73,424
% Chng.	(1.1)	0.4		
EPS (Rs.)	45.8	54.7	45.8	52.7
% Chng.	-	3.9		

### Key Financials - Consolidated

Y/e Mar	FY23	FY24E	FY25E	FY26E
Sales (Rs. bn)	439	486	536	596
EBITDA (Rs. bn)	118	130	149	174
Margin (%)	26.8	26.7	27.8	29.2
PAT (Rs. bn)	85	90	110	131
EPS (Rs.)	36.6	39.1	45.8	54.7
Gr. (%)	14.1	7.0	17.2	19.5
DPS (Rs.)	13.5	14.0	16.4	16.4
Yield (%)	1.0	1.0	1.2	1.2
RoE (%)	16.3	15.3	16.9	17.9
RoCE (%)	16.5	16.0	17.5	19.0
EV/Sales (x)	7.8	6.9	6.2	5.4
EV/EBITDA (x)	28.9	26.0	22.2	18.6
PE (x)	38.7	36.2	30.9	25.8
P/BV (x)	6.1	5.5	4.9	4.4

### Key Data

SUN.BO | SUNP IN

52-W High / Low	Rs.1,439 / Rs.922
Sensex / Nifty	71,752 / 21,726
Market Cap	Rs.3,395bn/ \$ 40,882m
Shares Outstanding	2,399m
3M Avg. Daily Value	Rs.2587.26m

### Shareholding Pattern (%)

Promoter's	54.48
Foreign	17.08
Domestic Institution	19.42
Public & Others	9.02
Promoter Pledge (Rs bn)	-

### Stock Performance (%)

	1M	6M	12M
Absolute	12.4	23.8	36.8
Relative	13.1	14.7	13.5

### Param Desai

paramdesai@plindia.com | 91-22-66322259

### Kushal Shah

kushalshah@plindia.com | 91-22-66322490

## Strong show in Specialty segment

### Quick Pointers:

- Global specialty sales in upward trajectory at \$276mn; up 24% YoY.
- Plans for EMA filing of Nidlegly in near term.

**Our FY24/FY25 earnings estimates broadly remains unchanged. Sun Pharma (SUNP) Q3FY24 EBIDTA was in line with our estimate, aided by domestic formulation and specialty sales. Overall specialty sales, GMs continue to remain healthy. Over last few years SUNP dependency on US generics has reduced and company's growth is more functional on specialty, RoW and domestic pharma business that has strong growth visibility. Furthermore, acquisition of Concert Pharma along with progress of other pipelines provides visibility to SUNP's specialty pipeline beyond FY25. We maintain 'BUY' rating at TP of Rs.1640 (Rs1280 earlier) based on 30x (26x earlier) FY26E earnings. SUNP remains our top pick in large cap space.**

**Healthy revenue growth aided by specialty & domestic formulation:** Revenues came in at Rs 124bn up 10% on YoY (up 2% QoQ). There was \$20mn milestone income booked in global specialty segment. Adj for milestone income revenue came in at Rs 122.5bn, we est 124bn. Domestic formulation growth was strong at 11% YoY. US sales adj for milestone came in \$457mn (\$430mn in Q2FY24). Taro sales came in at \$157mn; up 14% YoY. Global specialty sales came in at \$296mn; adj for milestone income came at \$276mn up 15% QoQ and 24% YoY. EM growth was muted with 1% YoY decline whereas ROW growth was healthy at 14% YoY. API sales were impacted by 10% YoY.

**EBITDA in-line aided by Milestone income:** EBITDA adj for milestone came in at Rs 32bn (up 15% YoY), we est Rs33.4bn. The miss was on account of lower EM sales and higher R&D. GMs adj for milestone came in at 77.2%, up 40bps QoQ. Ex Taro GMs were down by 50bps QoQ. R&D cost came in higher at Rs8.25bn, 6.7% of sales, up 23% YoY & 7% QoQ. Ex R&D other expenses came in higher; at Rs 31bn up 14% YoY and 2% QoQ. OPM adjusted for one off came in at 26.1%, down 70bps QoQ. Reported PAT of Rs24.6bn; in line with our est.

**Key concall takeaways:** The performance from global specialty business was driven by Ilumya, Cequa and Winlevi, partially offset by facility related issue in generic business across Mohali and Halol. gRevlimid sales continues to negligible during Q3FY24 while QoQ exTaro generic sales was flat QoQ. SUNP launched 28 new products during Q3FY24 in India and has guided for strong momentum from in licensed products. Launched 3 generic products in US on ex Taro basis. Mgmt cited that its specialty product Nildegly would be filed with European authorities by H1FY25. Further it intends to license GLP-1 from innovator companies. Its own GLP-1 has completed phase 1 trial. Specialty R&D accounted for 39% of total R&D spend for Q3FY24. Continues to invest in R&D pipeline for both global generics and specialty business. SUNP has rescheduled phase 2 trials for GL0034 and phase 3 trial for MM-II to H2FY25. SUNP has signed a definitive merger agreement with Taro to acquire the remaining stake for an agreed price of \$43 per share. Merger agreement stands subject to shareholder approval. EM sales were muted impacted by currency.

**Exhibit 1: 3QFY24 Result Overview (Rs mn): In line EBITDA aided by milestone income and specialty segment**

Y/e March	Q3FY24	Q3FY23	YoY gr. (%)	Q2FY24	QoQ gr. (%)	9MFY24	9MFY23	YoY gr. (%)
<b>Net Sales</b>	<b>1,23,807</b>	<b>1,12,410</b>	<b>10.1</b>	<b>1,21,924</b>	<b>1.5</b>	<b>3,65,140</b>	<b>3,29,550</b>	<b>10.8</b>
Raw Material	27,369	28,037	(2.4)	27,871	(1.8)	82,822	84,119	(1.5)
<i>% of Net Sales</i>	<i>22.1</i>	<i>24.9</i>		<i>22.9</i>		<i>22.7</i>	<i>25.5</i>	
Personnel Cost	23,633	20,371	16.0	23,644	(0.0)	71,297	61,165	16.6
<i>% of Net Sales</i>	<i>19.1</i>	<i>18.1</i>		<i>19.4</i>		<i>19.5</i>	<i>18.6</i>	
Others	39,282	33,934	15.8	38,275	2.6	1,12,066	94,830	18.2
<i>% of Net Sales</i>	<i>31.7</i>	<i>30.2</i>		<i>31.4</i>		<i>30.7</i>	<i>28.8</i>	
Total Expenditure	90,284	82,341	9.6	89,789	0.6	2,66,185	2,40,114	10.9
<b>EBITDA</b>	<b>33,523</b>	<b>30,069</b>	<b>11.5</b>	<b>32,135</b>	<b>4.3</b>	<b>98,955</b>	<b>89,436</b>	<b>10.6</b>
<i>Margin (%)</i>	<i>27.1</i>	<i>26.7</i>		<i>26.4</i>		<i>27.1</i>	<i>27.1</i>	
Depreciation	6,221	6,600	(5.7)	6,328	(1.7)	19,063	18,579	2.6
<b>EBIT</b>	<b>27,301</b>	<b>23,469</b>	<b>16.3</b>	<b>25,807</b>	<b>5.8</b>	<b>79,892</b>	<b>70,857</b>	<b>12.8</b>
Other Income	2,502	1,739	43.9	2,936	(14.8)	7,483	2,612	186.4
Interest	347	462	(24.8)	493	(29.5)	1,649	793	108.0
<b>PBT</b>	<b>29,456</b>	<b>24,746</b>	<b>19.0</b>	<b>28,250</b>	<b>4.3</b>	<b>85,725</b>	<b>72,677</b>	<b>18.0</b>
Total Taxes	4,323	2,834	52.5	3,901	10.8	12,905	6,247	106.6
<i>ETR (%)</i>	<i>14.7</i>	<i>11.5</i>		<i>13.8</i>		<i>15.1</i>	<i>8.6</i>	
<b>PAT</b>	<b>25,133</b>	<b>21,912</b>	<b>14.7</b>	<b>24,349</b>	<b>3.2</b>	<b>72,820</b>	<b>66,430</b>	<b>9.6</b>
Minority Interest	443	220	101.0	253	NA	601	550	9.3
Share in loss of associates	-	-		-		-	-	
<b>Reported PAT</b>	<b>24,690</b>	<b>21,691</b>	<b>13.8</b>	<b>24,096</b>	<b>2.5</b>	<b>72,220</b>	<b>65,880</b>	<b>9.6</b>
Exceptional items	(548)	31		341		3,002	989	
<b>Adj Pat</b>	<b>25,238</b>	<b>21,660</b>	<b>16.5</b>	<b>23,755</b>	<b>6.2</b>	<b>69,218</b>	<b>64,891</b>	<b>6.7</b>


Source: Company, PL

**Exhibit 2: Specialty and Domestic formulation aided strong performance**

Major sources of income	Q3FY24	Q3FY23	YoY gr. (%)	Q2FY24	QoQ gr. (%)	9MFY24	9MFY23	YoY gr. (%)
<b>API</b>	<b>4,660</b>	<b>5,154</b>	<b>(9.6)</b>	<b>4,972</b>	<b>(6.3)</b>	<b>15,028</b>	<b>15,871</b>	<b>(5.3)</b>
<i>% of Net Sales</i>	<i>3.8</i>	<i>4.6</i>		<i>4.1</i>		<i>4.2</i>	<i>4.9</i>	
<b>Formulation</b>	<b>1,16,263</b>	<b>1,05,299</b>	<b>10.4</b>	<b>1,14,379</b>	<b>1.6</b>	<b>3,42,447</b>	<b>3,07,854</b>	<b>11.2</b>
<i>% of Net Sales</i>	<i>95.6</i>	<i>94.9</i>		<i>95.3</i>		<i>95.3</i>	<i>94.6</i>	
India	37,785	33,919	11.4	38,425	(1.7)	1,11,814	1,02,390	9.2
<i>% of Net Sales</i>	<i>31.1</i>	<i>30.6</i>		<i>32.0</i>		<i>31.1</i>	<i>31.5</i>	
<b>International</b>	<b>78,478</b>	<b>71,380</b>	<b>9.9</b>	<b>75,953</b>	<b>3.3</b>	<b>2,30,633</b>	<b>2,05,464</b>	<b>12.2</b>
<i>% of Net Sales</i>	<i>64.6</i>	<i>64.3</i>		<i>63.3</i>		<i>64.2</i>	<i>63.1</i>	
US formulations	39,736	34,660	14.6	35,504	11.9	1,13,948	1,00,009	13.9
<i>% of Net Sales</i>	<i>32.7</i>	<i>31.2</i>		<i>29.6</i>		<i>31.7</i>	<i>30.7</i>	
ROW formulations	38,743	36,720	5.5	40,449	(4.2)	1,16,685	1,05,455	10.6
<i>% of Net Sales</i>	<i>31.9</i>	<i>33.1</i>		<i>33.7</i>		<i>32.5</i>	<i>32.4</i>	
Others	644	548	17.5	680	(5.3)	1,975	1,808	9.3
<b>Total Sales</b>	<b>1,21,568</b>	<b>1,11,001</b>	<b>9.5</b>	<b>1,20,031</b>	<b>1.3</b>	<b>3,59,450</b>	<b>3,25,533</b>	<b>10.4</b>


Source: Company, PL

**Exhibit 3: Sustained momentum from domestic formulation business**




Source: Company, PL

**Exhibit 4: Higher specialty sales led to incremental growth**




Source: Company, PL

**Exhibit 5: Lower EM sales largely impacted the performance**




Source: Company, PL

**Exhibit 6: Higher other expenses, R&D spend inches upward**



Source: Company, PL

**Exhibit 7: R&D spend remains accelerated**



Source: Company, PL

## Financials

### Income Statement (Rs m)

Y/e Mar	FY23	FY24E	FY25E	FY26E
<b>Net Revenues</b>	<b>4,38,857</b>	<b>4,86,348</b>	<b>5,36,409</b>	<b>5,95,968</b>
YoY gr. (%)	13.5	10.8	10.3	11.1
Cost of Goods Sold	1,06,622	1,10,674	1,21,768	1,35,269
Gross Profit	3,32,235	3,75,674	4,14,641	4,60,699
Margin (%)	75.7	77.2	77.3	77.3
Employee Cost	82,960	95,404	1,03,037	1,11,280
Other Expenses	1,31,546	1,50,621	1,62,477	1,75,303
<b>EBITDA</b>	<b>1,17,729</b>	<b>1,29,649</b>	<b>1,49,128</b>	<b>1,74,116</b>
YoY gr. (%)	14.9	10.1	15.0	16.8
Margin (%)	26.8	26.7	27.8	29.2
Depreciation and Amortization	25,294	25,874	27,168	28,718
<b>EBIT</b>	<b>92,435</b>	<b>1,03,775</b>	<b>1,21,960</b>	<b>1,45,398</b>
Margin (%)	21.1	21.3	22.7	24.4
Net Interest	1,720	2,100	2,100	2,100
Other Income	6,345	9,900	11,200	12,900
<b>Profit Before Tax</b>	<b>97,060</b>	<b>1,11,575</b>	<b>1,31,060</b>	<b>1,56,198</b>
Margin (%)	22.1	22.9	24.4	26.2
Total Tax	8,476	16,777	20,120	23,746
Effective tax rate (%)	8.7	15.0	15.4	15.2
<b>Profit after tax</b>	<b>88,584</b>	<b>94,797</b>	<b>1,10,941</b>	<b>1,32,452</b>
Minority interest	394	760	700	800
Share Profit from Associate	(479)	(200)	(300)	(300)
<b>Adjusted PAT</b>	<b>84,736</b>	<b>90,288</b>	<b>1,09,941</b>	<b>1,31,352</b>
YoY gr. (%)	158.9	6.6	21.8	19.5
Margin (%)	19.3	18.6	20.5	22.0
Extra Ord. Income / (Exp)	2,976	3,549	-	-
<b>Reported PAT</b>	<b>87,711</b>	<b>93,838</b>	<b>1,09,941</b>	<b>1,31,352</b>
YoY gr. (%)	14.1	7.0	17.2	19.5
Margin (%)	20.0	19.3	20.5	22.0
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	87,711	93,838	1,09,941	1,31,352
<b>Equity Shares O/s (m)</b>	<b>2,399</b>	<b>2,399</b>	<b>2,399</b>	<b>2,399</b>
<b>EPS (Rs)</b>	<b>36.6</b>	<b>39.1</b>	<b>45.8</b>	<b>54.7</b>

Source: Company Data, PL Research

### Balance Sheet Abstract (Rs m)

Y/e Mar	FY23	FY24E	FY25E	FY26E
<b>Non-Current Assets</b>				
<b>Gross Block</b>	<b>3,83,736</b>	<b>4,05,736</b>	<b>4,27,736</b>	<b>4,52,736</b>
Tangibles	2,49,878	2,64,204	2,78,530	2,94,809
Intangibles	1,33,858	1,41,532	1,49,207	1,57,927
<b>Acc: Dep / Amortization</b>	<b>1,86,564</b>	<b>2,12,438</b>	<b>2,39,606</b>	<b>2,68,324</b>
Tangibles	1,27,426	1,45,099	1,63,655	1,83,269
Intangibles	59,138	67,339	75,951	85,054
<b>Net fixed assets</b>	<b>1,97,172</b>	<b>1,93,298</b>	<b>1,88,130</b>	<b>1,84,413</b>
Tangibles	1,22,452	1,19,105	1,14,875	1,11,540
Intangibles	74,720	74,193	73,255	72,873
Capital Work In Progress	9,634	9,634	9,634	9,634
Goodwill	87,127	87,127	87,127	87,127
Non-Current Investments	1,48,301	1,48,301	1,48,301	1,48,301
Net Deferred tax assets	31,326	31,326	31,326	31,326
Other Non-Current Assets	-	-	-	-
<b>Current Assets</b>				
Investments	-	-	-	-
Inventories	1,05,131	1,13,061	1,32,152	1,46,992
Trade receivables	1,14,385	1,33,013	1,46,836	1,63,324
Cash & Bank Balance	57,703	82,141	1,18,850	1,78,484
Other Current Assets	55,922	55,922	55,922	55,922
<b>Total Assets</b>	<b>7,75,794</b>	<b>8,22,959</b>	<b>8,87,460</b>	<b>9,74,755</b>
<b>Equity</b>				
Equity Share Capital	2,399	2,399	2,399	2,399
Other Equity	5,57,555	6,14,154	6,84,790	7,76,839
<b>Total Networkth</b>	<b>5,59,954</b>	<b>6,16,553</b>	<b>6,87,190</b>	<b>7,79,238</b>
<b>Non-Current Liabilities</b>				
Long Term borrowings	5,599	5,599	5,599	5,599
Provisions	-	-	-	-
Other non current liabilities	-	-	-	-
<b>Current Liabilities</b>				
ST Debt / Current of LT Debt	63,260	48,260	33,260	18,260
Trade payables	56,815	59,856	66,076	73,496
Other current liabilities	88,290	89,856	91,500	93,227
<b>Total Equity &amp; Liabilities</b>	<b>7,75,794</b>	<b>8,22,959</b>	<b>8,87,460</b>	<b>9,74,755</b>

Source: Company Data, PL Research

**Cash Flow (Rs m)**

Y/e Mar	FY23	FY24E	FY25E	FY26E
PBT	97,060	1,11,575	1,31,060	1,56,198
Add. Depreciation	25,294	25,874	27,168	28,718
Add. Interest	1,720	2,100	2,100	2,100
Less Financial Other Income	6,345	9,900	11,200	12,900
Add. Other	(7,262)	(3,549)	-	-
Op. profit before WC changes	1,16,812	1,35,999	1,60,328	1,87,016
Net Changes-WC	(52,121)	(21,994)	(25,095)	(22,233)
Direct tax	(15,098)	(16,777)	(20,120)	(23,746)
<b>Net cash from Op. activities</b>	<b>49,593</b>	<b>97,228</b>	<b>1,15,113</b>	<b>1,41,038</b>
Capital expenditures	(67,714)	(22,000)	(22,000)	(25,000)
Interest / Dividend Income	-	-	-	-
Others	(10,674)	-	-	-
<b>Net Cash from Inv. activities</b>	<b>(78,388)</b>	<b>(22,000)</b>	<b>(22,000)</b>	<b>(25,000)</b>
Issue of share cap. / premium	-	-	-	-
Debt changes	51,297	(15,000)	(15,000)	(15,000)
Dividend paid	(25,189)	(33,689)	(39,304)	(39,304)
Interest paid	(1,720)	(2,100)	(2,100)	(2,100)
Others	11,777	-	-	-
<b>Net cash from Fin. activities</b>	<b>36,165</b>	<b>(50,789)</b>	<b>(56,404)</b>	<b>(56,404)</b>
<b>Net change in cash</b>	<b>7,370</b>	<b>24,438</b>	<b>36,709</b>	<b>59,634</b>
Free Cash Flow	28,737	75,228	93,113	1,16,038

Source: Company Data, PL Research

**Quarterly Financials (Rs m)**

Y/e Mar	Q4FY23	Q1FY24	Q2FY24	Q3FY24
<b>Net Revenue</b>	<b>1,09,307</b>	<b>1,19,408</b>	<b>1,21,924</b>	<b>1,23,807</b>
YoY gr. (%)	15.7	11.0	11.3	10.1
Raw Material Expenses	22,502	27,582	27,871	27,369
Gross Profit	86,805	91,827	94,053	96,438
Margin (%)	79.4	76.9	77.1	77.9
<b>EBITDA</b>	<b>28,293</b>	<b>33,297</b>	<b>32,135</b>	<b>33,523</b>
YoY gr. (%)	29.8	21.6	0.5	11.5
Margin (%)	25.9	27.9	26.4	27.1
Depreciation / Depletion	6,715	6,513	6,328	6,221
<b>EBIT</b>	<b>21,578</b>	<b>26,784</b>	<b>25,807</b>	<b>27,301</b>
Margin (%)	19.7	22.4	21.2	22.1
Net Interest	927	809	493	347
Other Income	3,733	2,044	2,936	2,502
<b>Profit before Tax</b>	<b>24,383</b>	<b>28,020</b>	<b>28,250</b>	<b>29,456</b>
Margin (%)	22.3	23.5	23.2	23.8
Total Tax	2,229	4,681	3,901	4,323
Effective tax rate (%)	9.1	16.7	13.8	14.7
<b>Profit after Tax</b>	<b>22,154</b>	<b>23,339</b>	<b>24,349</b>	<b>25,133</b>
Minority interest	323	(95)	253	443
Share Profit from Associates	-	-	-	-
<b>Adjusted PAT</b>	<b>19,845</b>	<b>20,225</b>	<b>23,755</b>	<b>25,238</b>
YoY gr. (%)	(187.1)	(1.9)	5.0	16.5
Margin (%)	18.2	16.9	19.5	20.4
Extra Ord. Income / (Exp)	1,986	3,208	341	(548)
<b>Reported PAT</b>	<b>21,831</b>	<b>23,434</b>	<b>24,096</b>	<b>24,690</b>
YoY gr. (%)	45.8	22.4	(3.8)	13.8
Margin (%)	20.0	19.6	19.8	19.9
Other Comprehensive Income	-	-	-	-
<b>Total Comprehensive Income</b>	<b>21,831</b>	<b>23,434</b>	<b>24,096</b>	<b>24,690</b>
Avg. Shares O/s (m)	2,399	2,399	2,399	2,399
<b>EPS (Rs)</b>	<b>9.1</b>	<b>9.8</b>	<b>10.0</b>	<b>10.3</b>

Source: Company Data, PL Research

**Key Financial Metrics**


Y/e Mar	FY23	FY24E	FY25E	FY26E
<b>Per Share(Rs)</b>				
EPS	36.6	39.1	45.8	54.7
CEPS	45.9	48.4	57.1	66.7
BVPS	233.4	257.0	286.4	324.8
FCF	12.0	31.4	38.8	48.4
DPS	13.5	14.0	16.4	16.4
<b>Return Ratio(%)</b>				
RoCE	16.5	16.0	17.5	19.0
ROIC	12.9	14.0	15.9	18.3
RoE	16.3	15.3	16.9	17.9
<b>Balance Sheet</b>				
Net Debt : Equity (x)	0.0	0.0	(0.1)	(0.2)
Net Working Capital (Days)	135	140	145	145
<b>Valuation(x)</b>				
PER	38.7	36.2	30.9	25.8
P/B	6.1	5.5	4.9	4.4
P/CEPS	45.9	48.4	57.1	66.7
EV/EBITDA	28.9	26.0	22.2	18.6
EV/Sales	7.8	6.9	6.2	5.4
Dividend Yield (%)	1.0	1.0	1.2	1.2

Source: Company Data, PL Research

**Key Operating Metrics**

Y/e Mar	FY23	FY24E	FY25E	FY26E
India Formulations	1,36,031	1,49,362	1,67,286	1,87,360
US Formulations	1,35,353	1,52,363	1,63,795	1,80,293
ROW Formulations	1,39,402	1,54,602	1,73,155	1,93,933
APIs	19,724	19,921	21,514	23,236

Source: Company Data, PL Research

**Price Chart**
**Recommendation History**


No.	Date	Rating	TP (Rs.)	Share Price (Rs.)
1	08-Jan-24	BUY	1,280	1,300
2	02-Nov-23	BUY	1,280	1,116
3	07-Oct-23	BUY	1,265	1,127
4	03-Aug-23	BUY	1,265	1,141
5	06-Jul-23	BUY	1,140	1,043
6	28-May-23	BUY	1,140	970
7	06-Apr-23	BUY	1,175	997

**Analyst Coverage Universe**

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Apollo Hospitals Enterprise	BUY	6,000	5,754
2	Aster DM Healthcare	BUY	430	417
3	Aurobindo Pharma	Accumulate	1,065	1,124
4	Cipla	Accumulate	1,400	1,375
5	Divi's Laboratories	Reduce	3,150	4,015
6	Dr. Reddy's Laboratories	Reduce	5,650	5,841
7	Eris Lifesciences	BUY	1,050	928
8	Fortis Healthcare	BUY	400	434
9	Glenmark Pharmaceuticals	Reduce	570	893
10	HealthCare Global Enterprises	BUY	420	371
11	Indoco Remedies	Accumulate	380	369
12	Ipca Laboratories	Hold	1,060	1,119
13	J.B. Chemicals & Pharmaceuticals	BUY	1,800	1,682
14	Jupiter Life Line Hospitals	BUY	1,310	1,138
15	Krishna Institute of Medical Sciences	BUY	2,000	2,000
16	Lupin	Hold	1,200	1,390
17	Max Healthcare Institute	BUY	675	715
18	Narayana Hrudayalaya	BUY	1,250	1,212
19	Sun Pharmaceutical Industries	BUY	1,280	1,300
20	Sunteck Realty	BUY	565	452
21	Torrent Pharmaceuticals	BUY	2,250	2,350
22	Zydus Lifesciences	Accumulate	670	714

**PL's Recommendation Nomenclature (Absolute Performance)**

<b>Buy</b>	: > 15%
<b>Accumulate</b>	: 5% to 15%
<b>Hold</b>	: +5% to -5%
<b>Reduce</b>	: -5% to -15%
<b>Sell</b>	: < -15%
<b>Not Rated (NR)</b>	: No specific call on the stock
<b>Under Review (UR)</b>	: Rating likely to change shortly





## ANALYST CERTIFICATION

### (Indian Clients)

We/I, Mr. Param Desai- MBA Finance, Mr. Kushal Shah- CFP, Passed CFA Level I Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

### (US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

## DISCLAIMER

### Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at [www.plindia.com](http://www.plindia.com).

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Param Desai- MBA Finance, Mr. Kushal Shah- CFP, Passed CFA Level I Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

### US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

---

### **Prabhudas Lilladher Pvt. Ltd.**

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209

[www.plindia.com](http://www.plindia.com)